Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 3
2(33.3%)
6Total
Phase 2(4)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07532603Phase 2Recruiting

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

Role: lead

NCT06431373Phase 3Active Not Recruiting

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Role: lead

NCT05437263Phase 3Active Not Recruiting

A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis

Role: lead

NCT05523765Phase 2Completed

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

Role: lead

NCT06433999Phase 2Completed

A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis

Role: lead

NCT06978725Phase 2Recruiting

A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

Role: lead

All 6 trials loaded